ELMD Quote, Financials, Valuation and Earnings

IRIDEX has a net margin of 12.06% compared to Electromed's net margin of -14.17%. Electromed's return on equity of 16.57% beat IRIDEX's return on equity of -218.69%.

Electromed has a consensus price target of $33.50, signalling upside risk potential of 81.87%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 86.92%. Given that IRIDEX has higher upside potential than Electromed, analysts believe IRIDEX is more attractive than Electromed.

Electromed has a beta of 0.413, which suggesting that the stock is 58.696% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.407%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $15.7M, which are larger than IRIDEX quarterly revenues of $11.9M. Electromed's net income of $1.9M is higher than IRIDEX's net income of -$1.7M. Notably, Electromed's price-to-earnings ratio is 23.32x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 2.69x versus 0.36x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Modular Medical has a net margin of 12.06% compared to Electromed's net margin of --. Electromed's return on equity of 16.57% beat Modular Medical's return on equity of --.

Electromed has a consensus price target of $33.50, signalling upside risk potential of 81.87%. On the other hand Modular Medical has an analysts' consensus of $8.00 which suggests that it could grow by 1034.59%. Given that Modular Medical has higher upside potential than Electromed, analysts believe Modular Medical is more attractive than Electromed.

Electromed has a beta of 0.413, which suggesting that the stock is 58.696% less volatile than S&P 500. In comparison Modular Medical has a beta of -4.943, suggesting its less volatile than the S&P 500 by 594.256%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Modular Medical pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $15.7M, which are larger than Modular Medical quarterly revenues of --. Electromed's net income of $1.9M is higher than Modular Medical's net income of -$4.9M. Notably, Electromed's price-to-earnings ratio is 23.32x while Modular Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 2.69x versus -- for Modular Medical. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 12.06% compared to Electromed's net margin of -35.24%. Electromed's return on equity of 16.57% beat Myomo's return on equity of -38.11%.

Electromed has a consensus price target of $33.50, signalling upside risk potential of 81.87%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 346.15%. Given that Myomo has higher upside potential than Electromed, analysts believe Myomo is more attractive than Electromed.

Electromed has a beta of 0.413, which suggesting that the stock is 58.696% less volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $15.7M, which are larger than Myomo quarterly revenues of $9.8M. Electromed's net income of $1.9M is higher than Myomo's net income of -$3.5M. Notably, Electromed's price-to-earnings ratio is 23.32x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 2.69x versus 1.97x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 12.06% compared to Electromed's net margin of -77.93%. Electromed's return on equity of 16.57% beat Stereotaxis's return on equity of -174.6%.

Electromed has a consensus price target of $33.50, signalling upside risk potential of 81.87%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 88.29%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

Electromed has a beta of 0.413, which suggesting that the stock is 58.696% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.440, suggesting its more volatile than the S&P 500 by 43.964%.

Electromed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Electromed pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Electromed quarterly revenues are $15.7M, which are larger than Stereotaxis quarterly revenues of $7.5M. Electromed's net income of $1.9M is higher than Stereotaxis's net income of -$5.8M. Notably, Electromed's price-to-earnings ratio is 23.32x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Electromed is 2.69x versus 7.49x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.